Characteristics of HSCT
| . | N = 60 . | % or range . |
|---|---|---|
| Age, median, y | 64 | 20-75 |
| Sex | ||
| Male | 31 | 52 |
| Female | 29 | 48 |
| AML subtype | ||
| MRC-AML | 41 | 68 |
| t-AML | 18 | 30 |
| Others | 1 | 2 |
| Disease status at time of HCT | ||
| CR | 53 | 88 |
| CRi | 1 | 2 |
| PR | 3 | 5 |
| Refractory | 3 | 5 |
| MRD status after CPX-351 induction | ||
| Negative | 18 | 30 |
| Positive | 7 | 12 |
| NA | 35 | - |
| Conditioning regimen | ||
| RIC | 41 | 68 |
| MAC | 16 | 27 |
| Donor | ||
| Matched related donor | 22 | 37 |
| Matched unrelated donor | 16 | 27 |
| Mismatched donor | 5 | 8 |
| Haploidentical donor | 17 | 28 |
| Stem cell source | ||
| Bone marrow | 6 | 10 |
| Peripheral blood | 49 | 82 |
| . | N = 60 . | % or range . |
|---|---|---|
| Age, median, y | 64 | 20-75 |
| Sex | ||
| Male | 31 | 52 |
| Female | 29 | 48 |
| AML subtype | ||
| MRC-AML | 41 | 68 |
| t-AML | 18 | 30 |
| Others | 1 | 2 |
| Disease status at time of HCT | ||
| CR | 53 | 88 |
| CRi | 1 | 2 |
| PR | 3 | 5 |
| Refractory | 3 | 5 |
| MRD status after CPX-351 induction | ||
| Negative | 18 | 30 |
| Positive | 7 | 12 |
| NA | 35 | - |
| Conditioning regimen | ||
| RIC | 41 | 68 |
| MAC | 16 | 27 |
| Donor | ||
| Matched related donor | 22 | 37 |
| Matched unrelated donor | 16 | 27 |
| Mismatched donor | 5 | 8 |
| Haploidentical donor | 17 | 28 |
| Stem cell source | ||
| Bone marrow | 6 | 10 |
| Peripheral blood | 49 | 82 |
MAC, myeloablative conditioning; NA, not available; RIC, reduced-intensity conditioning.